Tikcro Technologies Ltd. supports biotechnology projects originated in Israeli academic centers. Powered by a novel 3D antigen design technology, it generates “next generation” antibodies, currently in pre-clinical stage, blocking receptor / ligand surface domains of cancer immune modulators CTLA-4 and PD1.

TIKRF (Ordinary Share)

Last price;
Change (%)
Data as of 2017-10-22
Minimum 20 minute delay
Refresh quote
© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet